New Weight Loss Drug Shows 24% Weight Reduction: How GLP-1 Drugs Work (2025)

A woman who weighed 240 pounds lost 58 pounds in 48 weeks.

She didn't have surgery. She didn't go on an extreme diet. She took a weekly injection of an experimental drug called retatrutide.

That's 24% of her body weight gone. For context, the most successful weight loss drugs before this achieved around 15% reduction. Diet and exercise alone typically produce 3 to 5% loss.

The results, published in The New England Journal of Medicine, represent the most effective obesity medication ever tested in humans.

But retatrutide isn't alone. It's part of a new generation of weight loss drugs that work completely differently from anything that came before. They don't just suppress appetite or block fat absorption. They mimic hormones your gut naturally produces, hormones that regulate hunger, blood sugar, and how your body stores energy.

Drugs like Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide), and now retatrutide are changing how doctors treat obesity. They're also being prescribed off-label by millions of people who just want to lose weight, creating shortages, insurance battles, and a massive gray market of compounding pharmacies.

Here's how these drugs actually work, what the data really shows, who should and shouldn't take them, the side effects no one talks about enough, and what happens when you stop.

Traditional weight loss drugs worked on your brain or your digestive system in blunt ways.

Phentermine is a stimulant that suppresses appetite. Orlistat blocks fat absorption in your intestines (and causes oily, uncontrollable diarrhea). Contrave combines an antidepressant with an addiction medication to reduce cravings.

They all produce modest weight loss, around 5 to 10% on average. Most people regain the weight when they stop. And the side effects often make them intolerable.

The new drugs are different because they work with your body's existing hormone systems.

Your gut produces dozens of hormones that communicate with your brain about food, energy, and fullness.

The most important ones:

GLP-1 (glucagon-like peptide-1) is released when you eat. It signals your brain that you're full, slows down how fast your stomach empties, and tells your pancreas to produce insulin.

GIP (glucose-dependent insulinotropic polypeptide) does similar things but also affects how your body stores fat.

Glucagon tells your liver to release stored energy and affects how satisfied you feel after eating.

In people with obesity, these hormone signals often don't work properly. Your brain doesn't get the "stop eating" message as strongly. Your body stores more energy as fat. You feel hungry even when you've eaten enough calories.

The new weight loss drugs fix that communication breakdown.

Semaglutide is a GLP-1 receptor agonist. That means it mimics the GLP-1 hormone your gut naturally makes, but it lasts much longer.

Natural GLP-1 gets broken down by enzymes in your blood within minutes. Semaglutide is chemically modified to resist that breakdown. A single injection lasts a full week.

When you inject semaglutide, it:

Activates GLP-1 receptors in your brain (especially the hypothalamus and brainstem) that control appetite. You feel full faster and stay full longer.

Slows gastric emptying. Food stays in your stomach longer, which physically makes you feel fuller and reduces blood sugar spikes.

Increases insulin production when blood sugar is high. This helps if you have type 2 diabetes or prediabetes.

Reduces glucagon. Your liver releases less stored glucose, which helps lower blood sugar.

The result: you eat less because you're genuinely less hungry, not because you're forcing yourself to resist cravings.

In clinical trials, people on semaglutide (Wegovy at 2.4mg weekly dose) lost an average of 15% of their body weight over 68 weeks. About one-third of participants lost 20% or more.

That's comparable to gastric bypass surgery, which typically produces 25 to 30% weight loss.

Tirzepatide is a dual agonist. It activates both GLP-1 receptors and GIP receptors.

Why add GIP?

GIP enhances insulin secretion (helping with blood sugar) and appears to affect fat metabolism differently than GLP-1 alone. The combination seems to produce more weight loss with potentially fewer gastrointestinal side effects, though that's still being studied.

In the SURMOUNT-1 trial published in NEJM, people taking the highest dose of tirzepatide (15mg weekly) lost an average of 21% of their body weight over 72 weeks.

More than half of participants lost at least 20% of their weight. Some lost over 30%.

One patient in the trial went from 320 pounds to 210 pounds in 18 months.

These aren't typical results for everyone, but they show what's possible with this class of drugs.

Retatrutide takes it one step further. It's a triple agonist that activates GLP-1, GIP, and glucagon receptors.

Adding glucagon might sound counterintuitive (since glucagon raises blood sugar), but at the doses used, it appears to increase energy expenditure. Your body burns more calories at rest.

The Phase 2 trial results published in 2023 showed average weight loss of 24% at the highest dose (12mg weekly) after 48 weeks.

Some participants lost over 30% of their starting weight.

That's edging into bariatric surgery territory without the surgery.

Retatrutide is still in trials. It's not FDA approved yet. But if Phase 3 trials confirm these results, it could be available by 2026 or 2027.

Let's be clear about expectations.

You don't lose 24% overnight. Weight loss is gradual. Most people lose 1 to 2 pounds per week on average once they reach therapeutic dose.

The first few months show the most dramatic changes. Weight loss typically plateaus after 60 to 72 weeks, even if you keep taking the drug.

You still need to eat less. These drugs make it easier to eat less by reducing hunger, but you're not burning fat magically. You're consuming fewer calories, and that's why you lose weight.

Not everyone responds equally. In every trial, there are non-responders who lose less than 5%. Genetics, baseline metabolism, adherence, and other factors affect results.

The FDA approves medications based on specific criteria.

Wegovy (semaglutide 2.4mg) is approved for:

• Adults with BMI ≥30 (obesity)

• Adults with BMI ≥27 (overweight) plus at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol

• Adolescents age 12+ with obesity

Zepbound (tirzepatide) has similar approval criteria:

• BMI ≥30, or BMI ≥27 with weight-related health problems

Mounjaro (tirzepatide) is technically only FDA-approved for type 2 diabetes, but doctors prescribe it off-label for weight loss all the time.

Ozempic (semaglutide 1mg or 2mg) is also only approved for diabetes, but it became famous because people used it off-label for weight loss before Wegovy was available.

If you don't meet these criteria (if you're just looking to lose 10 vanity pounds), insurance won't cover it, and doctors technically shouldn't prescribe it, though many do for cash.

The most common side effects are gastrointestinal, and they're not minor.

Nausea affects 40 to 50% of people, especially when starting or increasing dose. For some it's mild queasiness. For others it's debilitating.

Vomiting happens in 10 to 25% of users.

Diarrhea or constipation. The drug slows your digestive system, which can go either direction. Some people get severe constipation. Others get unpredictable diarrhea.

Gastroparesis (stomach paralysis) is a rare but serious risk. Your stomach stops emptying properly. Food just sits there. In severe cases, people need feeding tubes or IV nutrition.

Gallstones. Rapid weight loss increases gallstone risk. Some people need their gallbladder removed.

Pancreatitis. Rare, but inflammation of the pancreas can be life-threatening.

Thyroid tumors. In rodent studies, GLP-1 drugs caused thyroid C-cell tumors. It's unclear if this happens in humans, but the drugs carry a black box warning. Don't take them if you or your family has a history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2.

Suicidal thoughts. Some case reports suggest a link between semaglutide and depression or suicidal ideation. The data isn't definitive, but European regulators are investigating.

"Ozempic face." Rapid fat loss, especially in older adults, can cause facial volume loss, making you look gaunt or aged. It's cosmetic, not dangerous, but it bothers people.

Most side effects improve after the first few weeks as your body adjusts. Starting at a low dose and increasing gradually helps.

But some people can't tolerate these drugs at all.

Here's the hard truth: for most people, the weight comes back.

In a study that followed patients one year after stopping semaglutide, participants regained about two-thirds of the weight they'd lost.

Why?

Because obesity is a chronic disease, not a temporary condition. The hormonal and metabolic factors that caused weight gain in the first place are still there. The drug was compensating for those factors. When you stop, they reassert themselves.

Your hunger comes back. Your metabolism may slow down (your body adapted to the lower weight and now burns fewer calories). You regain weight.

This doesn't mean the drugs don't work. It means they work as long as you take them, like blood pressure medication or antidepressants.

The current medical thinking: if these drugs work for you, you probably need to stay on them long-term.

This is where things get ugly.

Wegovy costs about $1,350 per month without insurance.

Zepbound is around $1,060 per month.

Mounjaro is similar, $1,000 to $1,200 monthly.

That's $12,000 to $16,000 per year. For life.

Insurance coverage is wildly inconsistent. Some plans cover GLP-1 drugs for diabetes but not for weight loss. Some cover them only if you have a BMI over 35. Some don't cover them at all.

Medicare specifically excludes coverage for weight loss drugs (a policy dating back to 2003 that Congress would need to change).

Manufacturer coupons exist but have strict eligibility requirements and often cap savings at a few months.

Because brand-name drugs are so expensive, a huge market emerged for compounded semaglutide and tirzepatide.

Compounding pharmacies can legally make custom formulations of drugs that are in shortage (which these have been). They charge $200 to $400 per month instead of $1,300.

But there are risks:

• Purity and dosing aren't FDA-verified. You're trusting the compounding pharmacy got it right.

• No long-term safety data on compounded versions.

• Legal gray area. If shortages end, compounding may become illegal.

Some telehealth companies prescribe compounded versions through online consultations. Convenience is high. Oversight is low.

Pregnant or breastfeeding women. Animal studies showed potential harm to fetuses.

People with personal or family history of medullary thyroid cancer or MEN2 syndrome.

People with a history of pancreatitis. GLP-1 drugs can trigger it.

People with severe gastroparesis or digestive motility disorders.

Anyone with active eating disorders. These drugs can make disordered eating worse.

People who can't afford long-term treatment. If you'll need to stop after a few months due to cost, the rebound weight gain may be psychologically and physically harmful.

Interestingly, these drugs do more than cause weight loss.

Cardiovascular benefits. The SELECT trial (2023) showed semaglutide reduced heart attacks and strokes by 20% in people with existing heart disease, independent of weight loss.

Kidney protection. GLP-1 drugs appear to slow progression of diabetic kidney disease.

Potential addiction treatment. Early research suggests GLP-1 drugs reduce cravings for alcohol, nicotine, and opioids. Trials are ongoing.

Fatty liver disease improvement. Non-alcoholic fatty liver disease often improves or resolves with these medications.

Sleep apnea reduction. Weight loss improves obstructive sleep apnea in many patients.

These weren't the original targets, but they're making researchers rethink what these drugs actually do.

Here's the equity problem.

Wealthy people can afford $1,300/month out of pocket. Everyone else depends on insurance.

If your insurance doesn't cover it (and many don't), you're stuck with:

• Compounded versions (cheaper, less regulated)

• Going without

• Medical tourism (people fly to Mexico or Canada for cheaper supply)

This creates a two-tier system where access to effective obesity treatment depends on wealth or insurance luck.

Some states are passing laws requiring insurance coverage. Others are not.

It's a mess, and it disproportionately affects the people who need these drugs most (lower-income individuals have higher obesity rates but worse insurance coverage).

For decades, obesity was treated as a willpower problem.

Eat less, move more. If you're still obese, you're not trying hard enough.

These drugs prove that's wrong.

Obesity is a disease of hormonal regulation, metabolism, and brain chemistry. It's not a moral failing.

People on semaglutide or tirzepatide aren't cheating. They're treating a medical condition with medication, the same way someone with depression takes an SSRI or someone with high cholesterol takes a statin.

The stigma is starting to shift, but it's slow.

If you have obesity (BMI ≥30) or overweight (BMI ≥27) with related health conditions like diabetes, high blood pressure, or heart disease, these drugs are worth discussing.

Questions to ask:

• Am I a good candidate based on my medical history?

• Which drug would you recommend and why?

• Will my insurance cover it?

• What are my options if insurance denies coverage?

• How will we monitor for side effects?

• What's the plan if I can't tolerate the side effects?

• What happens if I need to stop taking it eventually?

Be honest about your goals. If you want to lose 10 pounds for a wedding, that's not what these are for. If you've struggled with weight for years, have tried diet and exercise, and have health conditions worsening because of obesity, that's a different conversation.

We now have medications that produce 15 to 24% body weight reduction in clinical trials.

That's a massive leap forward from where we were five years ago.

But they're expensive, require lifelong use, have significant side effects for many people, and access is wildly unequal.

They're not magic. They're powerful tools that work by fixing broken hormone signaling in people whose bodies don't regulate hunger and energy storage normally.

For some people, these drugs are life-changing. They lose weight they've struggled with for decades. Their diabetes improves or goes into remission. Their blood pressure normalizes. They feel better.

For others, the side effects are intolerable, the cost is prohibitive, or the drugs just don't work.

This is the beginning of a new era in obesity medicine, not the end of the story.

Better drugs are coming. Oral versions are in development (no more weekly injections). Longer-acting formulations. Combinations that might work even better.

But right now, if you qualify, if you can access them, and if you can tolerate them, GLP-1 and multi-agonist drugs represent the most effective obesity treatment short of surgery.

And unlike surgery, you can stop if you need to.

Just know that stopping usually means the weight comes back. This is a long-term commitment, not a quick fix.

-New weight loss drugs (semaglutide, tirzepatide, retatrutide) produce 15 to 24% body weight reduction by mimicking gut hormones that control hunger and metabolism

-They work by activating GLP-1, GIP, and glucagon receptors in the brain and digestive system, making you feel full faster and stay full longer

-Approved for people with BMI ≥30 or BMI ≥27 with weight-related health conditions, not for cosmetic weight loss in healthy-weight individuals

-Common side effects include nausea (40 to 50% of users), vomiting, diarrhea, constipation, and rare but serious risks like pancreatitis and gallstones

-Most people regain about two-thirds of lost weight within a year of stopping, meaning likely lifelong treatment is needed

-Cost is $1,000 to $1,350 monthly with inconsistent insurance coverage, creating major access inequality

-Compounded versions cost $200 to $400 monthly but lack FDA oversight for purity and dosing accuracy

-Beyond weight loss, these drugs reduce heart attack and stroke risk by 20%, improve fatty liver disease, and may help treat addiction